CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions Incidence of contrast-induced acute kidney injury in a large cohort of all-comers undergoing percutaneous coronary intervention: Comparison of five contrast media Rotational Atherectomy Followed by Drug-Coated Balloon Dilation for Left Main In-Stent Restenosis in the Setting of Acute Coronary Syndrome Complicated with Right Coronary Chronic Total Occlusion Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease Two-Year Outcomes and Predictors of Target Lesion Revascularization for Non-Left Main Coronary Bifurcation Lesions Following Two-Stent Strategy With 2nd-Generation Drug-Eluting Stents Advances in Coronary No-Reflow Phenomenon-a Contemporary Review Switching P2Y12-receptor inhibitors in patients with coronary artery disease Complete Revascularization Versus Culprit Lesion Only in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease: A DANAMI-3-PRIMULTI Cardiac Magnetic Resonance Substudy Natural History of Spontaneous Coronary Artery Dissection With Spontaneous Angiographic Healing
|<<... 52 53 54 55 56 57 58 ...>>|

Clinical Trial2012 Jan 24;125(3):505-13.

JOURNAL：Circulation. Article Link

Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study

Gwon HC, Hahn JY, Kim HS et al. Keywords: DAPT duration; coronary artery disease; DES; platelet aggregation; inhibitors; stents; thrombosis

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top